Analysts Set Expectations for NewAmsterdam Pharma’s FY2028 Earnings (NASDAQ:NAMS)

NewAmsterdam Pharma (NASDAQ:NAMS) – Investment analysts at Leerink Partnrs reduced their FY2028 EPS estimates for NewAmsterdam Pharma in a research report issued to clients and investors on Thursday, August 8th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will post earnings per share of $0.39 for the year, down from their prior forecast of $0.40. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($2.24) per share.

NAMS has been the subject of a number of other reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, July 30th. TD Cowen began coverage on NewAmsterdam Pharma in a report on Wednesday, May 15th. They issued a “buy” rating for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $33.25.

NewAmsterdam Pharma Price Performance

NAMS stock opened at $17.22 on Monday. The firm has a 50 day simple moving average of $18.70 and a two-hundred day simple moving average of $20.19. NewAmsterdam Pharma has a one year low of $5.63 and a one year high of $26.35.

Insider Buying and Selling

In other NewAmsterdam Pharma news, CEO Michael H. Davidson purchased 5,000 shares of the business’s stock in a transaction on Thursday, June 20th. The stock was acquired at an average cost of $17.26 per share, for a total transaction of $86,300.00. Following the completion of the transaction, the chief executive officer now directly owns 204,784 shares in the company, valued at approximately $3,534,571.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 19.50% of the stock is owned by corporate insiders.

Institutional Trading of NewAmsterdam Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Parkman Healthcare Partners LLC increased its stake in shares of NewAmsterdam Pharma by 20.8% in the fourth quarter. Parkman Healthcare Partners LLC now owns 300,750 shares of the company’s stock worth $3,359,000 after buying an additional 51,726 shares during the period. TimesSquare Capital Management LLC purchased a new position in shares of NewAmsterdam Pharma in the first quarter valued at about $5,407,000. Opaleye Management Inc. bought a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at about $2,964,000. Jennison Associates LLC purchased a new stake in shares of NewAmsterdam Pharma during the first quarter worth about $22,015,000. Finally, Janus Henderson Group PLC bought a new stake in shares of NewAmsterdam Pharma in the first quarter worth about $15,018,000. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.